A Phase II, Randomized, Placebo-Controlled Study to Evaluate the Immunogenicity and the Safety of 2 Schedules of an Homologous Prime-Boost With the ALVAC-HIV vCP1452 in Chronically HIV-Infected Patients.

Trial Profile

A Phase II, Randomized, Placebo-Controlled Study to Evaluate the Immunogenicity and the Safety of 2 Schedules of an Homologous Prime-Boost With the ALVAC-HIV vCP1452 in Chronically HIV-Infected Patients.

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Jun 2011

At a glance

  • Drugs HIV vaccine vCP1452 (Primary)
  • Indications HIV infections
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms MANON-02
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 17 Dec 2009 Actual end date (Sep 2006) added as reported by ClinicalTrials.gov.
    • 11 Jul 2008 Primary endpoint results published in AIDS in July 2008
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top